Member Info for Doc83

Andybe4, Where did I say that?

“There has either been no urgency to get this drug out, *or the company has been told it has to wait in order for big pharma to make all their money first*.”

Best one yet.

If there’s one thing this stock has taught us, it’s that charts and TA tell us nothing!!

Lockie, why not go all out and just get everyone to declare their holding?!

Manifesto, nothing like giving yourself a bit of wiggle room when having a guess! A whole week :D

Anyway, I hope you’re right and even better would be to have *that* RNS.

Manifesto, you said they were taking advantage of the drop yesterday and loading up… “RNS incoming”?!

Come on, let’s be honest. We can’t work out from a load of trades going through if it’s Polygon, a large II or just PI trades. We need to be careful not to get too excited about some large(ish) trades going through and saying “Polygon ARE buying”. They might be. But we can’t be sure and it could inadvertently mislead.

Manifesto, has that TR1 arrived yet?

Manifesto, we will know if you were right in the next 60 minutes ;)

Blimey, Manifesto. You’re still going with this!

Let’s see if that TR1 one lands shortly… ;)

I’d be interested to know when analysing data, do they analyse one patient at a time, fully? Or would they say check one part of the data first, across all patients? Not sure if that makes sense.

But if analysing one patient completely, one at a time, then presumably they would have worked there way through the first 100-200 by the time the Ashfield agreement and jobs were advertised. That would be a similar data set to P2 and would have given them an idea of what results might be looking like.

I honestly have no idea on this so would welcome thoughts/comments.

HSD, state sponsored separatists more like.

Separatists… yeah right.

They’re still out in force tonight.

HSD - it seems you are right. I’ll have a dig around tomorrow but the Numis research says they place a “70% chance of success which is slightly above average”.

While I was having a quick scan, I came across this snippet which comments on long Covid chances. As it’s been discussed recently on here, I thought I’d post it:

“The trial of hospitalised COVID-19 patients showed that SNG001: reduced the odds of developing severe disease by 72% (81% in per protocol); increased the likelihood of recovery 2 to 3-fold; significantly reduced breathlessness; whilst also yielding encouraging hospital discharge data. As shown in Figure 8 (Time to Recovery), patients who received SNG001 were more than twice as likely to recover over the course of the treatment period compared to patients who received a placebo. Since Recovery is defined as OSCI score of 0 or 1, this equates to no limitation of activities (i.e. a full recovery, unlike RDV’s trial that extended to 2 and 3 on the OSCI scale). Figure 9 shows a similar trend in patients admitted with more severe disease and requiring oxygen at baseline. That over 60% of patients taking SNG001 made a full recovery from requiring oxygen at baseline is highly encouraging, and bodes well for the treatment of “long” SARS-CoV-2.”

So after all that, the jobs are back on?! Anyone know how to do a face palm emoji?

I haven’t got one member filtered. Russianbot close to being the first.

LOL @ Russianbot!

The wheels have come off this BB today. Absolutely nothing has changed, except for ONE more day has passed by. It’s definitely still early 2022, even if I am one of those who wanted results by now.

Time to wheel out my list of positives again:

- Previous trial results, including advancement to phase 3 in ACTIV US trial, are supportive of a positive outcome.
- 80% of phase 3 trials succeed.
- Excellent management team who have worked on this for many years.
- Recent recruitment drive to senior positions.
- Science supports the case for IFNb.
- Ingredient is a naturally occurring protein.
- Broad-spectrum antiviral, already proven (in vitro) to work on multiple variants of Covid-19.
- Different to current crop of therapeutics (inhalation).
- Could provide basis for other treatments, Asthma/COPD etc.
- Brokers positive. Numis price target of £9.90, Dr Paul Cuddon experienced in covering such stocks. Finncap also positive.
- Omicron, an even more urgent need than ever before for a variety of therapeutics.
- Vaccine hesitancy, more people becoming disillusioned with vaccines. May need to rely more on therapeutics.
- Represents a good risk/reward bet.
- Polygon/Polar taking significant stakes in Synairgen.
- Finncap upgrade.
- Commercialisation agreement signed with Ashfield, owned by UDG Healthcare (former FTSE250 member before being bought out in 2021).
- Several senior job roles advertised focusing on the US.
- Synairgen Incorporated set up in the US post P3 data being received.
- Video from Synairgen on 17/01/22 saying “we’re ready”.

LimaLiam - good point and that did cross my mind. In my early career I worked for one of the big banks. A role came up which was going to someone internally, but they still had to post the roles for external candidates.

Matterhorn - this seems almost too fast. The jobs were only posted just over a week ago. I would’ve thought it would take longer than that to get some decent candidates?

I know one thing… if this RNS really is only going to drop on a Monday, it’s going to be a looonnnng week on this board!

News of some more job adverts or a TR1 and we're back at 190-200p.

Nothing has changed today.

I’d suggest the most likely scenario is that they believe 100% in SNG and ignore the noise, buying the dips and shares from nervous investors.